Life Extension Final Clerance Sale

Life Extension Magazine

LE Magazine March 2004
image
Life Extension for the Brain
By Bruce Scali

Medications and Hormones
The most serious cases of memory loss require the most powerful remedies, prescribed and monitored by a physician. To complete our discussion of treatments for memory loss, we will briefly mention these prescription medications so that intelligent questions can be asked of a physician who is treating a patient for memory loss.

As noted earlier concerning depression medications addressing occipital lobe serotonin deficiencies, potent prescription medications are available to address parietal lobe acetylcholine deficits.32-34 These include Aricept® and Exelon®, among others. Regardless of which is prescribed, indications and side effects should be fully explained to the patient or caregiver.

Hormones, too, can be grouped into families associated with brain regions and functions. For example, testosterone, while commonly associated with sex drive, belongs to the frontal lobe/energy group. Hormones associated with the memory function include human growth hormone, vasopressin, DHEA, and pregnenolone. Hormone assessment and balancing should be included in a treatment plan for severe memory impairment.

Dollars and Sense
Memory decline can be identified at an early stage by tests administered in a primary care setting.35 When mild deficits are uncovered at their onset, simple remedies can be used to postpone the ravages of senility.

Early testing and treatment result in a short-term increase in health care expenditures, but the long-term benefits in both dollars saved and human suffering averted are many times more significant. In 1997, 90% of the 2.3 million people diagnosed with Alzheimer’s disease were over 60 years of age. In the US alone, treatment of Alzheimer’s costs $100 billion a year. Yet this immense figure spent on Alzheimer’s care may come to seem small when the majority of baby boomers turns 65.36 Coupled with the positive economic impact that a larger number of productive older people can have, the financial ramifications of early treatment of memory decline are irrefutable.

And the value of having loved ones remaining vital and connected to us longer is in itself incalculable.

The author gratefully acknowledges Eric Braverman, MD, and his PATH Medical Group for contributing research material and quotes used in this article. Dr. Braverman’s new book, The Edge Effect: How the Balanced Brain Can Give You an Advantage in Life, will be available from Sterling Publishers this spring.

SOURCES OF P300 TESTING

For information on P300 testing, contact the neurology department of your nearest hospital, or one of these doctors:

Eric Braverman, MD
New York, NY
888-231-7284

Richard Delaney, MD
Milton, MA
617-698-0715

Frank Duffy, MD
Cambridge, MA
617-355-7846

Ronald Goedeke, MD
Auckland, NZ
011-649-479-1199

Eugene Hong, MD
Singapore
011-65-8349-718

Young Chul Lee, MD
Seoul, South Korea
82-2-548-4711-2

Roger Nocera, MD
Scottsdale, AZ
602-686-4400

Titus Parker, MD
Virginia Beach, VA
757-226-8880

Andrea Raub, MD
San Diego, CA
858-724-1313

Murray Susser, MD
Los Angeles, CA
310-966-9194

Robert Thatcher, PhD
Bay Pines, FL
727-391-0890

Continued on Page 2 of 3

References

1. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975;12(3):189-98.

2. Derrer DS, Howieson DB, Mueller EA, Camicioli RM, Sexton G, Kaye JA. Memory testing in dementia: how much is enough? J Geriatric Psychiatr Neurol. 2001 Spring;14(1):1-6.

3. de Jager CA, Milwain E, Badge M. Early detection of isolated memory deficits in the elderly: the need for more sensitive neu- ropsychological tests. Psychol Med. 2002 Apr;32(3):483-91.

4. Royall DR, Palmer R, Chiodo LK, Polk MJ. Decline in learning ability best predicts future dementia type: the Freedom House study. Exper Aging Res. 2003 Oct- Dec;29(4):385-406

5. Braverman ER, Blum K. P300 (latency) event-related potential: an accurate predic- tor of memory impairment. Clin Electroencephalogr. 2003 Jul;34(3):124-39.

6. Sangal RB, Sangal JM. Topography of audi- tory and visual P300 in normal children. ClinElectroenceph. 1996 Jan;27(1):48-51.

7. Kilpelainen R, Kostinen A, Kononen M, Herrgard E, Partanen J, Karhu J. P300 sequence effects differ between children and adults for auditory stimuli. Psychophysiology. 1999 May;36(3):343-50.

8. Sangal RB,Sangal JM, Bellale C. P300 laten- cy and age: a quadratic regression explains their relationship from age 5 to 85. Clin Electroencephalogr. 1998 Jan;29(1):1-6.

9. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:52-76.

10. Himani A, Tandon OP, Bhatia MS. A study of P300 event-related evoked potential in the patients of major depression. Indian J Physiol Pharmacol. 1999 Jul;43(3):367-72.

11. Sanz M, Molina V, Martin-Loeches M, Calcedo A, Rubia FJ. Auditory P300 event- related potential and serotonin reuptake inhibitor treatment in obsessive-compulsive disorder patients. Psych Res. 2001 Feb 14;101(1):75-81.

12. Kurita A, Mochio S, Isogai Y. Changes in auditory P300 event-related potentials and brainstem evoked potentials in diabetes mel- litus. Acta Neurol Scand. 1995 Oct;92(4):319-23.

13. Bauer LO, Costa L, Hesselbrock VM. Effects of alcoholism, anxiety, and depres- sion on P300 in women: a pilot study. J Stud Alcohol. 2001 Sep;62(5):571-9.

14. Anokhin AP, Vedeniapin AB, Sirevaag EJ, et al. The P300 brain potential is reduced in smokers. Psychopharmacology. 2000 May;149(4):409-13.

15. Braverman ER, Blum K. Substance use dis- order exacerbates brain electrophysiological

abnormalities in a psychiatrically-ill popula- tion. Clin Electroencephalogr. 1996;27(4 Suppl):5-27.

16. Kilo J, Czerny M, Gorlitzer M, et al. Cardiopulmonary bypass affects cognitive brain function after coronary artery bypass grafting. Ann Thorac Surg. 2001 Dec;72(6):1926-32.

17. Tasman A, Hahn T, Maiste A. Menstrual cycle synchronized changes in brain stem auditory evoked potentials and visual evoked potentials. Biol Psychiatry. 1999 Jun 1;45(11):1516-9.

18. Attias J, Bleich A, Furman V, Zinger Y. Event-related potentials in post-traumatic stress disorder of combat origin. Biol Psychiatry. 1996 Sep 1;40(5):373-81.

19. Brown WS, Marsh JT, Wolcott D, et al. Cognitive function, mood and P3 latency: effects of amelioration of anemia in dialysis patients. Neuropsychologia. 1991;29(1):35-45.

20. Polich J, Moore AP, Wiederhold MD. P300 assessment of chronic fatigue syndrome. J Clin Neurophys. 1995 Mar;12(2):186-91.

21. Reeves RR, Struve FA, Patrick G, Payne DK, Thirstrup LL. Auditory and visual P300 cog- nitive evoked responses in patients with COPD: relationship to degree of pulmonary impairment. Clin Electroencephalogr. 1999 Jul;30(3):122-5.

22. Sirven J, Malamut B. Clinical Neurology of the Older Adult. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.

23. Yagi Y, Coburn KL, Estes KM, Arruda JE. Effects of aerobic exercise and gender on visual and auditory P300, reaction time, and accuracy. Eur J Appl Physiol Occup Physiol. 1999 Oct;80(5):402-8.

24. Koch M. Electromagnetic Fields: A Guide to Understanding What They Are and How to Reduce Your Exposure to Them. Alachua, FL: Teslatronics, Inc.;1991.

25. Modan B. Exposure to electromagnetic fields and brain malignancy: a newly discov- ered menace? Am J Ind Med. 1988;13(6):625-7.

26. Braverman E, Smith R, Smayda RJ, Blum K. Modification of P300 amplitude and other electrophysiological parameters of drug abuse by cranial electrical stimulation. Cur Ther Res. 1990;48:586-96.

27. Philip P, Demotes-Mainard J, Bourgeois M, Vincent JD. Efficiency of transcranial elec- trostimulation on anxiety and insomnia symptoms during a washout period in depressed patients. A double-blind study. Biol Psychiatry. 1991 Mar 1;29(5):451-6.

28. Krupitsky EM, Buralov AM, Karandashova GF, et al. The administration of transcranial electric treatment for affective disturbances therapy in alcoholic patients. Drug Alcohol Depend. 1991 Jan;27(1):1-6.

29. Lesser M, Kapklein C. The Brain Chemistry Diet. New York, NY: G.P. Putnam’s Sons; 2002.

30. Braverman E. The Healing Nutrients Within. 2nd ed. New Canaan, CT: Keats Publishing; 2003.

31. Cheng DH. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996 Dec 20;8(1):97-101.

32. d’Ardhuy XL, Boeijinga PH, Renault B, et al. Effects of serotonin-selective and classical antidepressants on the auditory P300 cogni- tive potential. Neuropsychobiology. 1999 Nov;40(4):207-13.

33. Hammond EJ, Meador KJ, Aung-Din R, Wilder BJ. Cholinergic modulation of human P3 event-related potentials. Neurology. 1987 Feb;37(2):346-50.

34. Dierks T, Frolich L, Ihl R, Maurer K. Event- related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry. 1994 Mar;27(2):72-4.

35. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN; US Preventive Services Task Force. Screening for dementia in primary care: a summary of the evidence for the US preventive services task force. Ann Intern Med. 2003 Jun 3;138(11):927-37.

36. Brookmeyer R, Gary S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998 Sep;88(9):1337-42.